Nuwellis (NASDAQ:NUWE – Get Free Report) and Delcath Systems (NASDAQ:DCTH – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Insider and Institutional Ownership
3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 1.6% of Nuwellis shares are owned by company insiders. Comparatively, 19.4% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Nuwellis and Delcath Systems”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nuwellis | $8.27 million | 0.34 | -$17.52 million | ($64.02) | -0.02 |
| Delcath Systems | $85.23 million | 4.46 | $2.70 million | $0.01 | 1,102.00 |
Delcath Systems has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Nuwellis has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.
Profitability
This table compares Nuwellis and Delcath Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nuwellis | -214.90% | -32,351.83% | -249.08% |
| Delcath Systems | 0.62% | 0.51% | 0.46% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for Nuwellis and Delcath Systems, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nuwellis | 1 | 0 | 0 | 0 | 1.00 |
| Delcath Systems | 2 | 0 | 5 | 0 | 2.43 |
Delcath Systems has a consensus target price of $22.50, suggesting a potential upside of 104.17%. Given Delcath Systems’ stronger consensus rating and higher possible upside, analysts clearly believe Delcath Systems is more favorable than Nuwellis.
Summary
Delcath Systems beats Nuwellis on 14 of the 14 factors compared between the two stocks.
About Nuwellis
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.
